A Prospecitve Multicenter, Observational Registry Study

AstraZeneca3,000 enrolled

Overview

This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.

To ensure a nationally representative cohort, a total of approximately 3000 participants will be enrolled from around 80 sites strategically selected from various geographic regions in China. The sites will include a mix of top-tier tertiary hospitals, regional medical centers, and representative secondary hospitals to accurately reflect real-world clinical practice at different levels of care. All enrolled participants will be followed up to 96 weeks according to the data collection schedule to assess long-term clinical outcomes. Investigators will obtain an informed consent from participants before screening. The CKD participants will only be considered enrolled in the study after providing written informed consent, followed by the assignment of a unique subject identifier. The data will be collected from medical records by the investigator and entered in a cloud-based electronic case report form (eCRF) using electronic data capture (EDC) system. The EDC system is a software tool designed to ensure quality assurance and facilitate data capture during the study. The data will be extracted from established medical records or other documents of the patients and transcribed to the EDC system.

Study Type

OBSERVATIONAL

Enrollment

3,000

Conditions

Chronic Kidney Disease

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patients aged ≥18 years. * Willing and able to provide written informed consent to participate in the study. * Confirmed CKD diagnosis at enrolment, defined by at least one of the following: * eGFR \<60 mL/min/1.73 m² for ≥3 months, OR * Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months Exclusion Criteria: * Having a life-threatening comorbidity with life expectancy \< 2 years. * Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months. * Pregnant or breastfeeding women. * Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment. * Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.

Locations (59)

Outcomes

Primary Outcomes

Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively

To determine the prevalence of HP, HF, HTN, and HK among patients with CKD

Time frame: baseline

Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)

To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Central Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

Anning, Yunnan - South Region, China

RECRUITING

Research Site

Beijing, Beijing, China

RECRUITING

Research Site

Cangzhou, Hebei - North Region, China

RECRUITING

Research Site

Caoxian County, Shandong Province, China

RECRUITING

Research Site

Changzhou, Jiangsu Province, China

RECRUITING

Research Site

Chengdu, Sichuan Province, China

RECRUITING

Research Site

Chongqing, Chongqing, China

RECRUITING

Research Site

Chongqing, Sichuan Province, China

RECRUITING

Research Site

Dalian, Liaoning, China

NOT_YET_RECRUITING

Research Site

Dongguan, Guangdong, China

RECRUITING

...and 49 more locations

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients with HK

To describe HK outcomes of HK recurrence for all CKD patients with HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients with HK

To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients with HK

To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of Percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of Percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of Proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of Proportion of patients achieving UPCR \< 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK

To describe the clinical indicators of Proportion of patients achieving UPER \<1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients with HP and HTN

To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients with HF

To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the additional clinical composite outcome of eGFR decline ≥40% for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the additional clinical composite outcome of ESRD for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the additional clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the additional clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the renal outcome of ≥40% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK

To describe the HK outcome of new-onset HK for all CKD patients and subgroups with HP, HF, HTN, or HK.

Time frame: Week 0 to week 96

Clinical indicators for CKD patients with HF

To describe the clinical indicators of Change of BNP from baseline over time in patients with CKD with HF.

Time frame: Week 0 to week 96

Secondary Outcomes

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of eGFR slope between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

The HCRU among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

To describe healthcare resource utilization (HCRU) among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicators eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Composite outcome of eGFR decline ≥50% between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of Change in eGFR from baseline over time between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of percent change in UACR from baseline over time between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of percent change in UPCR from baseline over time between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of percent change in UPER from baseline over time between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical indicators of proportion of patients achieving proteinuria control target over time between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP and HTN

To compare the clinical indicators of Change in systolic BP from baseline over time between CKD patients with or without HP, HTN

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP and HTN

To compare the clinical indicators of change in diastolic BP from baseline over time between CKD patients with or without HP, HTN

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HP and HTN

To compare the clinical indicators of proportion of patients achieving BP control target over time between CKD patients with or without HP, HTN

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HF

To compare the clinical indicators of Change of NT-proBNP from baseline over time between CKD patients with or without HF

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of change in systolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of change in diastolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups

To identify the factors associated with the clinical indicator of Proportion of patients achieving BP control target over time in patients with CKD overall, and in subgroups with HP,HTN

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF

To identify the factors associated with the clinical indicator of change of NT-proBNP from baseline over time in patients with CKD overall, and in subgroups with HF

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the composite outcome of eGFR decline ≥50% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the composite outcome of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the composite outcome of renal death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the composite outcome of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the renal outcomes of ≥50% eGFR decline from baseline in patients with CKD overall, and in subgroups with HP,HTN

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the renal outcomes of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the renal outcomes of RRT in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the renal outcomes of CKD stage progression in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with renal-related death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with CV outcomes of MACE in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with CV outcomes of HF in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with CV outcomes of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with CV outcomes of all-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with CV outcomes of all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

To identify the factors associated with HK outcomes of HK recurrence in patients with CKD overall, and in subgroups with HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

To identify the factors associated with HK outcomes of severe HK requiring hospitalisation in patients with CKD overall, and in subgroups with HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK

To identify the factors associated with HK outcomes of severe HK requiring emergency-department visits in patients with CKD overall, and in subgroups with HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of composite outcome of ESRD between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of composite outcome of renal death between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of composite outcome of CV death between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Renal outcomes of ≥50% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Renal outcomes of ESRD between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Renal outcomes of RRT between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of CKD stage progression between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Renal-related death between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of CV outcomes of MACE between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of CV outcomes of hHF between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of All-cause death between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of All-cause hospitalization between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HK

To compare the clinical outcomes of HK recurrence between CKD patients with or without HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HK

To compare the clinical outcomes of Severe HK requiring hospitalisation between CKD patients with or without HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HK

To compare the clinical outcomes of Severe HK requiring emergency-department visits between CKD patients with or without HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with All-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

Clinical indicators of CKD patients and CKD patients with HF

To compare the clinical indicators of Change of BNP from baseline over time between CKD patients with or without HF

Time frame: Week 0 to week 96

The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF

To identify the factors associated with the clinical indicator of change of BNP from baseline over time in patients with CKD overall, and in subgroups with HF

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with the composite outcome of eGFR decline ≥40% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK

Time frame: Week 0 to week 96

The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK

To identify the factors associated with HK outcomes of new-onset HK in patients with CKD overall, and in subgroups with HP, HF, HTN

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of Renal outcomes of ≥40% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96

Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK

To compare the clinical outcomes of HK outcome for new-onset HK between CKD patients with or without HP, HF, HTN, HK

Time frame: Week 0 to week 96